We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Mieke
Van Hemelrijck
mieke.vanhemelrijck@kcl.ac.uk
Miss
Anna
Haire
Anna.haire@kcl.ac.uk
Malignant neoplasms of male genital organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Widespread prostate cancer specific antigen (PSA) testing of asymptomatic men has dramatically increased the recorded incidence of prostate cancer in many western countries. It is now widely accepted that a large proportion of these men are overdiagnosed, because they have non-lethal disease, and overtreated with substantial side effects. To reduce overtreatment and adverse effects, active surveillance has emerged as a viable option that should be offered to patients with low-risk prostate cancer.
By monitoring disease progression, or lack thereof, and keeping the option to recommend radical local treatment open for a certain period of time, active surveillance might convey substantial benefits compared with routine initial prostatectomy or radiotherapy. There is, however, a lack of randomized evidence for when disease progression should trigger radical treatment with a curative intent in men who are on active surveillance.
To fill this problematic knowledge gap, the Scandinavian Prostatic Cancer Group is promoting a large multicentre randomized trial, called SPCG-17. The aim of this trial is to test the safety of an active surveillance protocol comparing current practice with standardized triggers for initiation of curative treatment. The primary endpoint is progression-free survival, based on the cumulative incidence of indicators of prostate cancer progression. This trial is open and running in Sweden and Finland, and has approval to begin in Norway. We propose to run a similar RCT in the UK which will add to the findings from SPCG-17.
Currently, across the UK, decisions to re-biopsy and initiate curative treatment are not guided by any set criteria and tend to be at the clinician’s discretion. The PCASTT-UK trial aims to test a set of standardised rules around when to undertake a repeat biopsy and when to initiate curative treatment for men on active surveillance. In all other respects standard care will remain the same.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Management of Care;Active Monitoring;
You can take part if:
You may not be able to take part if:
- Not a candidate for Active Surveillance (according to criteria listed above) - Not able to give informed consent - Not proficient in English
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by King's College London and funded by Swedish Research Council; Cancerfonden (Swedish Cancer Society); Nordic Cancer Union; Uppsala County Council; .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 39898
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
